eujobs.coEU jobs in brussels
Post a JobHeadhunter

argenx

General Information

Identification Code: 438972049913-07
Entity Form: bv
Registration Category: Companies & groups
Registration Date: 4/21/2023
Last Update: 4/15/2024
EP Accredited Number: 0

Mission & Interests

Goals: We are a commercial-stage, global, fully-integrated biopharma company developing a deep pipeline of differentiated therapies for the treatment of severe autoimmune diseases. By combining our suite of antibody engineering technologies with the disease biology expertise of our research collaborators, we aim to translate immunology breakthroughs into a pipeline of novel antibody-based medicines through our discovery engine, the IIP. We have a particular focus on rare, autoimmune diseases that fit into our growing commercial franchises focused on neurology, hematology and rheumatology, dermatology and nephrology.
Interests Represented: Promotes their own interests or the collective interests of their members
Interests:
  • Business and industry
  • Competition
  • Digital economy and society
  • Economy, finance and the euro
  • Employment and social affairs
  • Institutional affairs
  • Public health
  • Research and innovation
  • Single market
  • Taxation
  • Trade
Levels of Interest:
  • global
  • european

Activities

Main EU Legislative Proposals: At this stage, argenx activities in the field of public policy in general and at EU level in particular is fairly limited and include legislative and policy monitoring, and some direct and indirect engagement via trade association EUCOPE. We expect this engagement to increase in the context of the Reform of EU pharmaceutical legislation. In addition, argenx supports All United for MG - a pan european patient group coalition (https://www.allunitedformg.eu/) which is expected to present a series of policy recommendations to EU officials with different implications for EU policies and legislation. Key legislative topics relate to EU pharmaceutical and health policy and in particular Reform of the EU pharmaceutical legislation published on April 26. https://health.ec.europa.eu/publications/proposal-regulation-laying-down-union-procedures-authorisation-and-supervision-medicinal-products_en
Communication Activities: argenx supported myastenia gravis patient advocacy groups in the all united for MG campaign, which includes some disease awareness activities and events at European Parliament. While supported by argenx, those activities are driven by Patient Advocacy Groups across Europe.
Inter-institutional or Unofficial Groupings: N/A

Head Office

Address: Industriepark Zwijnaarde 7, 9052 Gent
Post Code: 9052
City: Ghent
Country: BELGIUM
Phone: [object Object]

EU Office

Address: Industriepark Zwijnaarde 7, 9052 Gent
Post Code: 9052
City: Ghent
Country: BELGIUM
Phone: [object Object]

Financial Data

New Organisation: false
Closed Year: [object Object]
Current Year: [object Object]
Complementary Information: Portland PR Europe Limited has supported argenx in 2022 and 2023. On a go forward basis, argenx may not use intermediary any further. Transparency register will be updated accordingly.

Membership Information

Members10 Percent: 0
Members25 Percent: 1
Members50 Percent: 0
Members75 Percent: 0
Members: 1
Members F T E: 0.25
Info Members: argenx Patient Advocacy and Public Policy team for the entire European region is composed of two FTEs. Those FTEs are responsible for a broad range of activities across countries in Europe Middle East and Africa. In addition, activities at EU level are limited and therefore constitute a very limited share of the work of the patient advocacy and public policy team (see above)

Structure

Structure Type: Structure
Is Member Of: n.a.
Organisation Members: EUCOPE https://www.eucope.org/ EURORDIS (ERTC) https://www.eurordis.org/